IconOVir Announces New Preclinical Data Showcasing Best-in-Class Potential of ICVB-1042, its Lead Oncolytic Virus, at SITC 2022
— ICVB-1042 demonstrates selective replication, broad tropism and anti-tumor activity across multiple in vitro and in vivo models — — Proprietary Ad5/Ad34 mutation improves viral entry into target tumor cells, enhancing tropism — — On track to initiate Phase 1 trial in solid tumors in 1H 2023 — SAN DIEGO, CA., November 10, 2022 – […]